Since the 1940s, dermal fillers have been used to fill facial defects. Initially, silicone-based and then collagen-based fillers were used, but it was the introduction of hyaluronic acid (HA) based dermal fillers that brought these treatments into the mainstream. HA-based fillers offer a more natural feel than collagen and are also reversible, making them a popular choice for non-surgical rejuvenation. Galderma launched a new syringe and packaging for all Restylane products in the fall of 2020, and continues to seek opportunities in the market.
Dr. Dayan is looking forward to new directions and products, as the safety profile of Restylane has been established with more than 3,000 clinical studies. New indications are being evaluated and studies are being developed for areas such as tear ducts and temples, which could be exciting for both providers and patients. What began as a single filler intended for nasolabial folds and puppet lines has expanded to a whole family of Restylane products, each aimed at different areas of the face.
RESTYLANE is the original non-animal stabilized hyaluronic acid filler with more than 25 years of achievements and more than 50 million treatments worldwide. The RESTYLANE product portfolio includes RESTYLANE, RESTYLANE LYFT, RESTYLANE KYSSE, RESTYLANE VOLYME, RESTYLANE DEFYNE, RESTYLANE REFYNE, RESTYLANE EYELIGHT and RESTYLANE SKINBOOSTERS.